Showing results (11-20 of 343) with videos related to
Sort By:
Pageof 35
Journal of Neurology, Neurosurgery, and Psychiatry|August 12, 2015
Cerebrovascular injury as a risk factor for amyotrophic lateral sclerosisMartin R Turner, Raph Goldacre, Kevin Talbot, et al.Brain Communications|August 14, 2023
Primary care blood tests show lipid profile changes in pre-symptomatic amyotrophic lateral sclerosisAlexander G Thompson, Rachael Marsden, Kevin Talbot, et al.Acta Neuropathologica|April 11, 2014
FTLD-ALS of TDP-43 type and SCA2 in a family with a full ataxin-2 polyglutamine expansionDirk Bäumer, Simon Z East, Bing Tseu, et al.Human Molecular Genetics|November 4, 2009
Pre-symptomatic development of lower motor neuron connectivity in a mouse model of severe spinal muscular atrophyLyndsay M Murray, Sheena Lee, Dirk Bäumer, et al.Brain : a Journal of Neurology|November 15, 2011
Integration of structural and functional magnetic resonance imaging in amyotrophic lateral sclerosisGwenaëlle Douaud, Nicola Filippini, Steven Knight, et al.Molecular Neurobiology|February 21, 2018
Towards a TDP-43-Based Biomarker for ALS and FTLDEmily Feneberg, Elizabeth Gray, Olaf Ansorge, et al.Annals of Clinical and Translational Neurology|August 29, 2025
A Validated Model to Predict Severe Weight Loss in Amyotrophic Lateral SclerosisDavid G Lester, Kevin Talbot, Martin R Turner, et al.The Lancet. Neurology|December 17, 2008
Biomarkers in amyotrophic lateral sclerosisMartin R Turner, Matthew C Kiernan, P Nigel Leigh, et al.Journal of Neurology, Neurosurgery, and Psychiatry|May 16, 2025
Progression and life expectancy in primary lateral sclerosisDavid G Lester, Alexander G Thompson, Kevin Talbot, et al.Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|February 12, 2016
The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onsetMalcolm Proudfoot, Ashley Jones, Kevin Talbot, et al.Pageof 35